GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer

GSK plc (GSK) announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary, advanced or recurrent endometrial cancer.The regulatory body has now approved Jemperli in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary, advanced or recurrent endometrial cancer who are candidates for systemic therapy in the European Union (“EU”).The approval ...